Packaging Repackaging — Apply packaging and repackaging requirements to maintain compliance - Mpje

SECTION 1

Historical Context & Motivation

The practice of repackaging medications — transferring a drug product from its original manufacturer's container into a different container for dispensing or distribution — has been an integral part of pharmacy practice for centuries. Early apothecaries routinely compounded and packaged medications from bulk ingredients, but as industrialized pharmaceutical manufacturing grew in the twentieth century, the distinction between manufacturing, compounding, and repackaging became critically important from both a regulatory and patient-safety standpoint. Contamination events, mislabeling incidents, and stability failures throughout the past century drove legislators and regulatory bodies to establish progressively stricter rules governing how, when, and by whom drug products may be repackaged.

1938 • Federal Food, Drug, and Cosmetic Act (FDCA)

Following the sulfanilamide disaster of 1937, Congress enacted the FDCA, which introduced requirements for drug safety, proper labeling, and adequate packaging to prevent adulteration. This landmark legislation established the FDA's authority over drug packaging standards.

1970 • Poison Prevention Packaging Act (PPPA)

The CPSC was granted authority to require child-resistant packaging for most prescription drugs and certain OTC medications. Pharmacies repackaging medications became obligated to use child-resistant containers unless specific exemptions applied.

1990 • USP Chapter ⟨1178⟩ Good Repackaging Practices

The United States Pharmacopeia published comprehensive guidance on repackaging standards, establishing expectations for beyond-use dating, environmental controls, labeling, and quality assurance procedures for pharmacies and repackagers.

2013 • Drug Quality and Security Act (DQSA)

Enacted after the 2012 New England Compounding Center meningitis outbreak, the DQSA clarified the regulatory boundary between compounding and manufacturing, with significant implications for entities performing large-scale repackaging operations.

2020s • FDA & USP Modernization Efforts

Ongoing revisions to USP General Chapters ⟨797⟩ and ⟨795⟩, along with updated FDA guidance documents, continue to refine expectations for sterile and non-sterile repackaging, track-and-trace requirements, and unit-dose packaging standards.

These regulatory milestones raise a fundamental question that every pharmacy professional must be able to answer: When does the act of placing a medication into a new container cross the line from routine pharmacy practice into an activity that triggers additional federal and state regulatory obligations? Understanding this boundary — and the specific requirements that apply on either side — is essential for MPJE preparation and for maintaining compliance in practice.

SECTION 2

Core Principles & Definitions

Before exploring specific regulatory requirements, it is essential to establish a precise vocabulary. The terms packaging, repackaging, compounding, and manufacturing carry distinct legal meanings, and conflating them can lead to serious compliance violations. The following foundational principles form the conceptual framework upon which all packaging and repackaging regulations rest.

Repackaging vs. Compounding

Repackaging involves transferring a commercially manufactured drug product from its original container into a different container without altering the drug's formulation. Compounding, by contrast, involves combining, mixing, or altering ingredients to create a new preparation. This distinction is critical because each activity triggers different regulatory pathways.

Beyond-Use Date (BUD) Assignment

Once a drug is removed from its original container, the manufacturer's expiration date no longer applies. The pharmacy must assign a beyond-use date (BUD) based on USP standards, stability data, and the characteristics of the new container. The BUD must never exceed the original manufacturer's expiration date.

Container-Closure Integrity

The new container must provide protection equivalent to or better than the original packaging. Factors include light resistance, moisture barrier properties, child-resistant closure requirements under the PPPA, and tamper-evident features when applicable.

Labeling Compliance

Repackaged medications must carry a label that includes the drug name, strength, lot number, BUD, storage conditions, and the identity of the repackager. For patient-specific dispensing, additional state-mandated labeling elements (prescriber name, patient name, directions) must also appear.

Regulatory Classification of the Repackager

A pharmacy repackaging medications for its own patients operates under state pharmacy law and USP standards. An entity that repackages medications for sale or distribution to other facilities must register with the FDA as a repackager and comply with current Good Manufacturing Practices (cGMPs).

✦

KEY TAKEAWAY

Think of repackaging like transferring food from a manufacturer's sealed bag into a smaller container at home. The moment you open the original package, you assume responsibility for maintaining quality — controlling temperature, preventing contamination, and tracking how long the food remains safe. In pharmacy, this responsibility is formalized through beyond-use dating, container-closure requirements, and labeling mandates — each designed to ensure the patient receives a product that is as safe and effective as the original.

SECTION 3

Visual Explanation — The Repackaging Compliance Pathway

This decision pathway illustrates the regulatory fork that occurs the moment a pharmacist decides to transfer a medication from its original container. The left branch (pharmacy repackaging for own patients) is governed primarily by state pharmacy law and USP standards, while the right branch (repackaging for distribution to other facilities) triggers FDA registration and cGMP obligations. Both pathways share common requirements for proper container selection, labeling, and beyond-use dating.

The diagram above captures the essential decision logic that a pharmacist or pharmacy manager must apply whenever contemplating repackaging. Note the critical branch point at the second diamond: the determination of whether repackaged products will be used for the pharmacy's own patients versus distributed to external facilities fundamentally changes the regulatory framework that governs the activity. A community pharmacy placing tablets into unit-dose blister packs for its long-term care patients operates under state board of pharmacy rules and USP guidance, whereas a facility that repackages medications for sale to hospitals across multiple states must meet the full rigor of FDA manufacturing standards, including current Good Manufacturing Practices and Drug Supply Chain Security Act serialization requirements.

SECTION 4

How Repackaging Requirements Work in Practice

Beyond-Use Date (BUD) Determination

The assignment of a beyond-use date is one of the most practically significant aspects of repackaging compliance. Unlike an expiration date — which is determined by the manufacturer through formal stability testing — the beyond-use date is assigned by the pharmacy or repackager and represents the date after which the repackaged product should no longer be used. USP Chapter ⟨1178⟩ provides the framework for BUD assignment when a pharmacy repackages solid oral dosage forms into unit-dose containers.

USP ⟨1178⟩ BUD RULE FOR SOLID ORAL DOSAGE FORMS

BUD = min(6 months from repackaging date, 25% of remaining time to manufacturer expiration, manufacturer expiration date)

Where: 6 months = maximum BUD if no stability data supports a longer period; 25% of remaining time = conservative stability estimate when repackaging into less protective containers; the BUD can never exceed the manufacturer's original expiration date.

Container-Closure System Selection

The USP classifies containers as well-closed, tight, or light-resistant based on their protective characteristics. When a drug's monograph specifies storage in a "tight, light-resistant container," the pharmacy must select a repackaging container that meets or exceeds those specifications. Failure to match the manufacturer's container specifications can accelerate degradation and compromise therapeutic efficacy, potentially creating both a safety hazard and a regulatory violation.

CHILD-RESISTANT PACKAGING RULE (PPPA)

All Rx medications → CR packaging UNLESS: (1) Patient or prescriber requests non-CR, OR (2) Drug is on CPSC exempt list

The Poison Prevention Packaging Act requires child-resistant (CR) closures for nearly all prescription medications. A blanket waiver (applying to all prescriptions for a patient) is permissible, but the patient's request must be documented. Sublingual nitroglycerin tablets and certain oral contraceptive packages in manufacturer dispensing packs are examples of CPSC exemptions.

Labeling Requirements for Repackaged Products

Labeling is the mechanism by which critical information travels with the repackaged product throughout the supply chain and ultimately to the patient. For pharmacy-repackaged unit-dose products, the label must include at minimum: the drug name (brand and/or generic), strength, lot number, beyond-use date, storage conditions, and the name of the repackaging pharmacy. When the product is intended for direct patient dispensing, state-specific labeling requirements (prescriber, patient identification, directions for use) also apply.

SECTION 5

Detailed Breakdown — Types of Repackaging & Regulatory Classification

Repackaging activities exist on a spectrum from simple pharmacy-level unit-dosing to large-scale industrial repackaging operations. The regulatory burden increases proportionally with the scale and scope of distribution. Understanding where a particular repackaging activity falls on this spectrum is essential for determining which set of rules applies.

The regulatory spectrum of repackaging activities ranges from pharmacy-level unit-dosing (governed by state law and USP) through outsourcing facilities (FDA-registered under Section 503B of the FDCA) to full-scale commercial repackagers (subject to the complete range of FDA manufacturing requirements). Note that all three tiers share common foundational requirements for proper labeling, container integrity, storage conditions, and quality assurance documentation.

Feature	Pharmacy (Own Patients)	503B Outsourcing	FDA Repackager
FDA Registration	Not required	Required	Required + listing
cGMP Compliance	Not required (USP standards)	Required	Required
BUD Determination	USP ⟨1178⟩ default rules	Stability data required	Full ICH stability testing
Prescription Required	Yes (patient-specific)	No (anticipatory)	No (commercial distribution)
Adverse Event Reporting	State-level (MedWatch voluntary)	Mandatory to FDA	Mandatory to FDA
DSCSA Serialization	Not required	Limited requirements	Full serialization

Comparison of regulatory requirements across three tiers of repackaging entities

SECTION 6

Worked Example — Repackaging Compliance Scenario

Consider the following real-world scenario: a hospital pharmacy receives a bulk bottle of metformin 500 mg tablets (1,000-count) from the manufacturer, with a manufacturer's expiration date of December 2026. The pharmacy needs to repackage these tablets into unit-dose blister packs for use on the hospital's medication carts. Today's date is March 15, 2025. The drug monograph specifies storage in a "tight, light-resistant container" at controlled room temperature (20–25°C).

Repackaging Metformin 500 mg into Unit-Dose Blister Packs

1
Step 1 — Verify Authority and Scope

Confirm that this repackaging activity is within the pharmacy's scope of practice. Because the hospital pharmacy is repackaging for its own patients (patients admitted to the hospital), this falls under state pharmacy law and USP standards — not FDA manufacturing requirements. No FDA registration is needed for this activity.

Activity classified as pharmacy-level repackaging (own patients).
2
Step 2 — Select Appropriate Container

The metformin monograph requires a "tight, light-resistant container." Select unit-dose blister packaging made of opaque or amber-tinted foil that provides a moisture barrier consistent with USP definitions of a "tight" container. Since these are unit-dose packages for institutional use within the hospital, the PPPA child-resistant closure requirement does not apply (institutional exemption), but the container must still meet the USP protective specifications.

Amber foil unit-dose blister selected; CR exemption applies (institutional use).
3
Step 3 — Calculate Beyond-Use Date (BUD)

Apply the USP ⟨1178⟩ BUD rule. The manufacturer's expiration date is December 2026. The remaining time from the repackaging date (March 15, 2025) to the expiration date is approximately 21 months. Calculate 25% of remaining time: 21 months × 0.25 = 5.25 months ≈ 5 months. Compare this to the 6-month maximum default: 5 months < 6 months, so the 25% rule is more restrictive. The BUD would be August 15, 2025 (approximately 5 months from the repackaging date).

BUD assigned: August 15, 2025 (25% of remaining time = ~5 months, which is less than the 6-month default).
4
Step 4 — Label the Repackaged Product

Each unit-dose blister pack must bear a label including: drug name (Metformin HCl), strength (500 mg), manufacturer lot number (from the original bulk bottle), the pharmacy's internal lot or control number, beyond-use date (08/15/2025), storage conditions ("Store at 20–25°C; protect from light and moisture"), and the name of the repackaging pharmacy. For institutional unit-dose use, patient-specific labeling is not applied at this stage — it occurs when the dose is pulled for administration.

Label complete with all required elements: drug name, strength, lot #, BUD, storage, and repackager identity.
5
Step 5 — Document and Establish Quality Controls

Create a repackaging log entry that records the date of repackaging, the drug product, manufacturer lot number, quantity repackaged, the pharmacy's assigned control number, the BUD, the identity of the pharmacist who supervised or verified the repackaging, and the identity of the technician who performed it. Retain this record for the period required by state law (commonly at least 2 years beyond the BUD). Implement a visual inspection quality check to verify correct tablet appearance and confirm each blister is properly sealed.

Repackaging log completed; QA visual inspection passed; records retained per state requirements.

SECTION 7

Common Compliance Pitfalls & How to Avoid Them

Understanding the rules is only half the challenge; recognizing where pharmacies most frequently stumble is equally important for both exam preparation and professional practice. The table below identifies the most common compliance failures associated with repackaging and provides corresponding best practices for avoidance. Many MPJE questions test the ability to identify subtle violations that a less careful practitioner might overlook.

Common Pitfall	Why It Violates Compliance	Best Practice
Using manufacturer expiration date as BUD	The original stability data applies only to the original container-closure system. Once repackaged, degradation kinetics may change.	Apply USP ⟨1178⟩ BUD rules: the lesser of 6 months or 25% of remaining time, never exceeding the manufacturer's expiration date.
Omitting lot number on unit-dose label	Without a lot number, a recall cannot be traced to affected units. This violates both USP labeling requirements and FDA recall protocols.	Always include both the manufacturer's lot number and the pharmacy's internal control number on every repackaged unit.
Ignoring container specifications	Placing a light-sensitive drug into clear packaging or a moisture-sensitive drug into a non-tight container accelerates degradation.	Consult the drug's USP monograph for container specifications before selecting repackaging materials.
Failing to document repackaging activities	Without records, the pharmacy cannot demonstrate compliance during a Board of Pharmacy inspection or trace the source of a quality issue.	Maintain a repackaging log with all required data elements; retain records per state law requirements.
Distributing repackaged products to other pharmacies without FDA registration	This crosses the line from pharmacy practice into manufacturing or wholesale distribution, requiring FDA registration and cGMP compliance.	Limit repackaging to own-use patients unless the facility is properly registered with the FDA as a repackager or 503B outsourcing facility.

Common repackaging compliance pitfalls and corresponding best practices

⚠

KEY TAKEAWAY

The most frequently tested repackaging concept on the MPJE is the BUD assignment — specifically, the difference between the manufacturer's expiration date and the pharmacy's beyond-use date, and why the manufacturer's date cannot simply be carried forward after repackaging. Think of it like transferring milk from a sealed jug into a glass pitcher: the original shelf life assumed the factory-sealed container. Once you open and pour, the clock accelerates because the new container provides different environmental protection. The same principle applies to medications removed from their original closure systems.

SECTION 8

Connection to Advanced Regulatory Frameworks

Repackaging compliance does not exist in isolation. It intersects with several advanced regulatory frameworks that healthcare students and pharmacy professionals must understand as they progress in their careers. The Drug Supply Chain Security Act (DSCSA), sterile compounding standards under USP ⟨797⟩, and the evolving landscape of 503B outsourcing facilities all share conceptual and regulatory overlap with repackaging requirements. Understanding these connections strengthens your ability to navigate complex compliance scenarios on the MPJE and in professional practice.

Concept	Basic Repackaging (This Lesson)	Advanced Framework
Product Traceability	Internal lot tracking and repackaging logs maintained by the pharmacy	DSCSA requires full interoperable electronic tracing with serialized product identifiers across the entire supply chain by 2027
Sterile Products	Non-sterile solid oral dosage forms repackaged into unit-dose containers	USP ⟨797⟩ governs sterile repackaging (e.g., drawing up syringes from vials) with ISO-classified cleanroom requirements and shorter BUDs
Scale of Operations	Small-scale, patient-specific or institutional use within a single pharmacy	503B outsourcing facilities may repackage at large scale without patient-specific prescriptions, bridging pharmacy and manufacturing
Quality Standards	USP ⟨1178⟩ guidelines and state BOP requirements	Current Good Manufacturing Practices (21 CFR Parts 210/211) with full process validation, environmental monitoring, and batch release testing
Recall Authority	State BOP-directed recall using pharmacy's internal records	FDA-directed recall with mandatory public notification, lot-level tracing, and potential market withdrawal

Comparison: basic pharmacy repackaging vs. advanced regulatory frameworks

As you advance in your pharmacy education and career, you will encounter situations where these frameworks overlap. For example, a hospital pharmacy that repackages sterile injectable products into individual syringes for operating room use must comply with both USP ⟨797⟩ sterile compounding standards and USP ⟨1178⟩ repackaging principles. The BUD assignment for such a product would be governed by the more restrictive of the two standards. The DSCSA's product tracing requirements, which become fully enforceable by November 2027, will add another layer of compliance for any entity involved in the pharmaceutical distribution chain, including repackagers.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A pharmacist repackages amlodipine 5 mg tablets from a manufacturer's 500-count bottle into amber vials containing 30 tablets each for dispensing to the pharmacy's outpatient customers. The pharmacist uses the manufacturer's expiration date as the beyond-use date on the new vials. Is this practice compliant? Explain your reasoning.

Show answer

No, this practice is not compliant. Once a drug product is removed from its original manufacturer container, the manufacturer's stability data no longer fully applies because the original container-closure integrity has been compromised. Under USP ⟨1178⟩, the pharmacy must assign a beyond-use date that is the lesser of 6 months from the date of repackaging or 25% of the time remaining until the manufacturer's expiration date, and in no case may it exceed the original expiration date. Simply carrying forward the manufacturer's expiration date ignores the potential for accelerated degradation in the new container and constitutes a violation of USP repackaging standards.

Question 2: BASIC CALCULATION

A pharmacy repackages lisinopril 10 mg tablets on June 1, 2025. The manufacturer's expiration date on the original bottle is February 2027. Using USP ⟨1178⟩ default BUD rules for solid oral dosage forms repackaged into unit-dose containers, calculate the appropriate beyond-use date.

Show answer

First, determine the remaining time from the repackaging date to the manufacturer's expiration: June 1, 2025 to February 2027 = approximately 20 months. Next, calculate 25% of the remaining time: 20 months × 0.25 = 5 months. Compare this to the 6-month default maximum: 5 months is less than 6 months, so the 25% rule is the limiting factor. The BUD would be approximately November 1, 2025 (5 months from the June 1, 2025 repackaging date). This date also does not exceed the manufacturer's expiration of February 2027, so the final BUD is November 1, 2025.

Question 3: INTERMEDIATE

A long-term care pharmacy repackages multiple medications into unit-dose bingo cards for nursing home patients. One of the medications, nifedipine extended-release 30 mg tablets, has a monograph specification requiring storage in a "tight, light-resistant container" and is known to be photosensitive. The pharmacy uses clear plastic blister packaging for all its unit-dose products. Identify all compliance issues in this scenario and describe the corrective actions needed.

Show answer

There are two primary compliance issues. First, clear plastic blister packaging does not meet the "light-resistant" container specification required by the nifedipine monograph. Nifedipine is photosensitive and can undergo significant degradation when exposed to light, potentially reducing efficacy and generating toxic degradation products. The corrective action is to use opaque or amber-tinted foil blister packaging that meets the USP definition of a light-resistant container. Second, the pharmacy should verify that the blister material also qualifies as a "tight" container per USP standards, meaning it provides adequate protection from moisture. Using a one-size-fits-all clear plastic blister for all medications demonstrates a failure to consult individual drug monograph container specifications — a required step in the repackaging process. The pharmacy should implement a procedure requiring monograph review before selecting packaging materials for each drug product.

Question 4: APPLIED

A community pharmacy has been approached by three neighboring independent pharmacies that want to purchase unit-dose repackaged medications from it, rather than repackaging their own products. The pharmacy manager believes that because the pharmacy holds a state pharmacy license, it can legally sell repackaged medications to other pharmacies. Analyze the regulatory implications of this arrangement and advise the pharmacy manager.

Show answer

The pharmacy manager's understanding is incorrect and this arrangement would create serious regulatory violations. A pharmacy that repackages medications solely for its own patients operates under state pharmacy law and USP standards. However, the moment the pharmacy begins distributing repackaged products to other pharmacies, it crosses the line from pharmacy practice into either wholesale distribution or manufacturing/repackaging as defined by federal law. This would require FDA registration as a repackager (subject to 21 CFR Parts 210/211 cGMP requirements), possibly a state wholesale distributor license, compliance with the DSCSA's product tracing requirements, assignment of a new NDC number for its repackaged products, and formal stability testing to support expiration dating. Alternatively, the pharmacy could register as a 503B outsourcing facility under Section 503B of the FDCA, which would allow it to distribute without patient-specific prescriptions but would still require FDA registration, cGMP compliance, and adverse event reporting. The pharmacy manager should be advised that proceeding without proper registration could result in FDA enforcement action, state board of pharmacy disciplinary proceedings, and potential criminal liability.

Question 5: CRITICAL THINKING

A hospital pharmacy director proposes the following efficiency measure: rather than repackaging individual tablets from bulk bottles as needed, the pharmacy will repackage the entire contents of bulk bottles into unit-dose blisters on the day they are received, thereby creating a large inventory of pre-made unit-dose products. The director argues this will reduce labor costs and improve medication cart fill times. Evaluate this proposal from a compliance, quality, and patient-safety perspective. What factors should the director consider, and what safeguards would you recommend?

Show answer

This proposal raises several important compliance, quality, and practical considerations. From a compliance standpoint, the approach is not inherently prohibited, but the director must ensure that the assigned BUDs under USP ⟨1178⟩ are applied correctly. Repackaging the entire contents at once means all units share the same BUD, which starts from the date of repackaging — not the date of eventual use. If usage is slow, units may expire before they are administered, leading to waste. From a quality perspective, repackaging in large batches increases the risk of errors: a single mislabeled batch run could affect hundreds of doses rather than a small number. The director should implement robust quality assurance checks including independent pharmacist verification of every batch, systematic visual inspection of repackaged units, and environmental monitoring to ensure controlled room temperature and humidity are maintained in the repackaging area. From a patient-safety standpoint, a large inventory of identical-appearing blister packs increases the importance of clear, accurate labeling including drug name, strength, and lot number. The director should also consider implementing a first-in-first-out (FIFO) inventory system for repackaged products, conducting periodic reviews to identify and remove expired units, maintaining meticulous batch records to enable tracing in case of a recall, and ensuring adequate training for all personnel involved in the repackaging process. The efficiency gains are legitimate, but they must be balanced against increased quality assurance obligations to maintain compliance and protect patients.

SUMMARY

Packaging & Repackaging Compliance — Summary Review

Summary

Pharmacy repackaging — transferring a commercially manufactured drug from its original container into a different container — triggers a defined set of regulatory obligations that vary based on the scale and intended distribution of the repackaged product. At the pharmacy level (own patients), the activity is governed by state pharmacy law and USP ⟨1178⟩, requiring proper container-closure selection that matches the drug monograph, assignment of a beyond-use date (BUD) using the lesser of 6 months or 25% of remaining time to manufacturer expiration, child-resistant closures per the PPPA (with documented exceptions), complete labeling (drug name, strength, lot number, BUD, storage conditions, repackager identity), and thorough documentation in a repackaging log.

When repackaging extends beyond own-patient use into distribution to other facilities, the regulatory framework escalates dramatically: FDA registration, cGMP compliance, DSCSA serialization, and adverse event reporting become mandatory. The critical skill for the MPJE is the ability to correctly classify a repackaging activity, determine which regulatory tier applies, and identify violations related to BUD assignment, container selection, labeling, and scope of distribution.